Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Cerebrospinal fluid biomarkers in Parkinson disease.

Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, Calabresi P.

Nat Rev Neurol. 2013 Mar;9(3):131-40. doi: 10.1038/nrneurol.2013.10. Epub 2013 Feb 19. Review.

PMID:
23419373
2.

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.

Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J.

Ann Neurol. 2011 Mar;69(3):570-80. doi: 10.1002/ana.22311. Epub 2011 Mar 11.

3.

CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls.

Herbert MK, Eeftens JM, Aerts MB, Esselink RA, Bloem BR, Kuiperij HB, Verbeek MM.

Parkinsonism Relat Disord. 2014 Jan;20(1):112-5. doi: 10.1016/j.parkreldis.2013.09.003. Epub 2013 Sep 12.

PMID:
24075122
4.

DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function.

Shi M, Furay AR, Sossi V, Aasly JO, Armaly J, Wang Y, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Leverenz JB, Stoessl AJ, Zhang J.

Neurobiol Aging. 2012 Apr;33(4):836.e5-7. doi: 10.1016/j.neurobiolaging.2011.09.015. Epub 2011 Oct 21.

5.

α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease.

Waragai M, Sekiyama K, Sekigawa A, Takamatsu Y, Fujita M, Hashimoto M.

Int J Mol Sci. 2010 Oct 29;11(11):4257-66. doi: 10.3390/ijms11114257. Review.

6.

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.

Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J.

Brain. 2010 Mar;133(Pt 3):713-26. doi: 10.1093/brain/awq008. Epub 2010 Feb 15.

7.

Biochemical premotor biomarkers for Parkinson's disease.

Mollenhauer B, Zhang J.

Mov Disord. 2012 Apr 15;27(5):644-50. doi: 10.1002/mds.24956. Review.

8.

Problems associated with fluid biomarkers for Parkinson's disease.

Nyhlén J, Constantinescu R, Zetterberg H.

Biomark Med. 2010 Oct;4(5):671-81. doi: 10.2217/bmm.10.84. Review.

PMID:
20945980
9.

Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.

Bäckström DC, Eriksson Domellöf M, Linder J, Olsson B, Öhrfelt A, Trupp M, Zetterberg H, Blennow K, Forsgren L.

JAMA Neurol. 2015 Oct;72(10):1175-82. doi: 10.1001/jamaneurol.2015.1449.

PMID:
26258692
10.

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.

Kruse N, Schlossmacher MG, Schulz-Schaeffer WJ, Vanmechelen E, Vanderstichele H, El-Agnaf OM, Mollenhauer B.

PLoS One. 2016 Apr 26;11(4):e0153564. doi: 10.1371/journal.pone.0153564. eCollection 2016.

11.

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM; Parkinson's Progression Markers Initiative.

JAMA Neurol. 2013 Oct;70(10):1277-87.

12.

Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease.

Waragai M, Wei J, Fujita M, Nakai M, Ho GJ, Masliah E, Akatsu H, Yamada T, Hashimoto M.

Biochem Biophys Res Commun. 2006 Jul 7;345(3):967-72. Epub 2006 May 11.

PMID:
16707095
13.

Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.

Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T.

Parkinsonism Relat Disord. 2015 Jul;21(7):758-64. doi: 10.1016/j.parkreldis.2015.04.027. Epub 2015 May 2.

PMID:
25971633
14.

The role of biomarkers and imaging in Parkinson's disease.

Algarni MA, Stoessl AJ.

Expert Rev Neurother. 2016;16(2):187-203. doi: 10.1586/14737175.2016.1135056. Epub 2016 Feb 1. Review.

PMID:
26829357
15.

Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease.

Zhang J, Mattison HA, Liu C, Ginghina C, Auinger P, McDermott MP, Stewart T, Kang UJ; Parkinson Study Group DATATOP Investigators, Cain KC, Shi M.

Acta Neuropathol. 2013 Nov;126(5):671-82. doi: 10.1007/s00401-013-1121-x. Epub 2013 May 4.

16.

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Håkan W, Decraemer H, Någga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O.

Arch Neurol. 2012 Nov;69(11):1445-52.

PMID:
22925882
17.

Parkinson disease: Progress towards a molecular biomarker for Parkinson disease.

Foulds P, Mann DM, Mitchell JD, Allsop D.

Nat Rev Neurol. 2010 Jul;6(7):359-61. doi: 10.1038/nrneurol.2010.78. No abstract available.

PMID:
20639912
18.

Biomarkers in Parkinson's disease: a funder's perspective.

Frasier M, Chowdhury S, Eberling J, Sherer T.

Biomark Med. 2010 Oct;4(5):723-9. doi: 10.2217/bmm.10.89.

PMID:
20945984
19.

[Proteomic biomarkers in Parkinson's disease].

Bandrés S, Durán R, Barrero F, Ramírez M, Vives F.

Rev Neurol. 2014 Feb 16;58(4):166-74. Review. Spanish.

20.

Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers.

Aasly JO, Shi M, Sossi V, Stewart T, Johansen KK, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Kim HM, Leverenz JB, Ginghina C, Armaly J, Edwards KL, Snapinn KW, Stoessl AJ, Zhang J.

Neurology. 2012 Jan 3;78(1):55-61. doi: 10.1212/WNL.0b013e31823ed101. Epub 2011 Dec 14.

Supplemental Content

Support Center